Literature DB >> 25690574

[Focal therapy for prostate cancer: German version].

V Kasivisvanathan1, T T Shah, I Donaldson, A Kanthabalan, C M Moore, M Emberton, H U Ahmed.   

Abstract

Focal therapy is a treatment strategy for men with localized prostate cancer that may serve as an alternative option to radical therapy. A number of minimally invasive ablative technologies are available to deliver treatment, and the energies most commonly used include high-intensity focused ultrasound and cryotherapy. The benefit of a tissue-preserving approach is the limitation of damage to key structures such as the neurovascular bundles, external urinary sphincter, rectal mucosa and bladder neck. This in turn minimizes side effects typically associated with radical therapies whilst also aiming to maintain oncological control. Over 30 single-centre studies of focal therapy have been published to date reporting excellent continence rates, good potency rates and acceptable short-term oncological outcomes. However, there are a number of controversial aspects associated with focal therapy including the index lesion hypothesis, patient selection criteria, assessment of treatment effect and the lack of medium- and long-term oncological outcomes. In the process of the adoption of new technology, there is a limited window of opportunity to provide this evidence in well-designed prospective trials. Men should be allowed to benefit from the potential advantages of this novel treatment whilst under close surveillance. An English version of this article is available under dx.doi.org/10.1007/s00120-014-3734-7.

Entities:  

Mesh:

Year:  2015        PMID: 25690574     DOI: 10.1007/s00120-014-3668-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  27 in total

Review 1.  Role of MRI in follow-up after focal therapy for prostate carcinoma.

Authors:  Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

2.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.

Authors:  Arnauld Villers; Philippe Puech; Damien Mouton; Xavier Leroy; Charles Ballereau; Laurent Lemaitre
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

Review 3.  Can we deliver randomized trials of focal therapy in prostate cancer?

Authors:  Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-04-22       Impact factor: 66.675

4.  Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy.

Authors:  B A Kletscher; J Qian; D G Bostwick; P E Andrews; H Zincke
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

5.  Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience.

Authors:  Ted Lee; Neil Mendhiratta; Dan Sperling; Herbert Lepor
Journal:  Rev Urol       Date:  2014

6.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

Review 7.  Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?

Authors:  Hashim Uddin Ahmed; Manit Arya; Alex Freeman; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-11       Impact factor: 41.316

8.  Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy.

Authors:  Gary Onik; Winston Barzell
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

Review 9.  Controversies in papillary microcarcinoma of the thyroid.

Authors:  Monique Piersanti; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Authors:  Massimo Valerio; Louise Dickinson; Afia Ali; Navin Ramachandran; Ian Donaldson; Alex Freeman; Hashim U Ahmed; Mark Emberton
Journal:  Contemp Clin Trials       Date:  2014-07-26       Impact factor: 2.226

View more
  2 in total

Review 1.  [Irreversible electroporation. Current value for focal treatment of prostate cancer].

Authors:  J J Wendler; R Ganzer; B Hadaschik; A Blana; T Henkel; K U Köhrmann; S Machtens; A Roosen; G Salomon; L Sentker; U Witzsch; H P Schlemmer; D Baumunk; J Köllermann; M Schostak; U B Liehr
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

Review 2.  Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.

Authors:  J J Wendler; R Ganzer; B Hadaschik; A Blana; T Henkel; K U Köhrmann; S Machtens; A Roosen; G Salomon; L Sentker; U Witzsch; H P Schlemmer; D Baumunk; J Köllermann; M Schostak; U B Liehr
Journal:  World J Urol       Date:  2016-05-04       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.